Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial† (Q56690209)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 March 2014

Language	Label	Description	Also known as
English	Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial†	scientific article published on 10 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Fernando A. Soares

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

J Bines

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

R Dienstmann

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

R M Obadia

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

L G P Branco

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

D C Quintella

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

T M Castro

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

P G Camacho

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

M E F Costa

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

10 March 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

831-836

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Additive endocrine therapy for advanced breast cancer - back to the future

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Androgen receptor expression and breast cancer survival in postmenopausal women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

The sequential use of endocrine treatment for advanced breast cancer: where are we?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU015

21 January 2018

Identifiers

10.1093/ANNONC/MDU015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615412%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56690209&oldid=1970458127"